Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh Saudi Arabia.
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Strathclyde, UK.
Niger J Clin Pract. 2024 Aug 1;27(8):965-971. doi: 10.4103/njcp.njcp_805_23. Epub 2024 Aug 26.
Type 2 diabetes is a common chronic disease that continues to increase in prevalence globally and is a major healthcare burden. Diabetes and hypertension frequently occur concurrently, and the use of antihypertensive agents is common in diabetic patients. One antihypertensive agent, verapamil, has tentatively shown potentially positive effects on glycemic control in assorted pre-clinical models.
To evaluate the effect of verapamil on glycemic control in hypertensive type 2 diabetic patients.
Type 2 diabetic hypertensive patients were recruited from King Fahad Medical City, Riyadh, KSA, to receive oral verapamil therapy. Blood pressure and glycometabolic parameters, including fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), C-peptide, and homeostatic model assessment insulin resistance (HOMA-IR), were monitored at baseline and after 6 months of verapamil therapy.
Thirty-five patients (16 male, 19 female) with a mean age of 57.2 years were recruited. The use of verapamil was associated with non-significant decreases in HbA1c, FPG, C-peptide, and HOMA-IR. However, a sub-group of 17 participants showed a decrease in HbA1c that was ≥0.5%. Univariate logistic regression showed that baseline BMI, HOMA-IR, and C-peptide were significantly (P < 0.05) associated with HbA1c reductions of ≥0.5%.
Verapamil is metabolically neutral and allows the stabilization of glycometabolic parameters in type 2 diabetic individuals. Additional research exploring the mechanism behind the variable response to verapamil therapy is warranted.
2 型糖尿病是一种常见的慢性疾病，在全球范围内患病率持续上升，是主要的医疗保健负担。糖尿病和高血压经常同时发生，糖尿病患者常使用抗高血压药物。一种抗高血压药物维拉帕米在各种临床前模型中对血糖控制显示出潜在的积极作用。
评估维拉帕米对 2 型糖尿病高血压患者血糖控制的影响。
从沙特阿拉伯利雅得的法赫德国王医疗城招募 2 型糖尿病高血压患者接受口服维拉帕米治疗。在基线和维拉帕米治疗 6 个月后监测血压和糖代谢参数，包括空腹血糖（FPG）、糖化血红蛋白（HbA1c）、C 肽和稳态模型评估胰岛素抵抗（HOMA-IR）。
共招募了 35 名患者（16 名男性，19 名女性），平均年龄为 57.2 岁。使用维拉帕米与 HbA1c、FPG、C 肽和 HOMA-IR 的非显著降低相关。然而，17 名参与者中有一部分的 HbA1c 降低了≥0.5%。单变量逻辑回归显示，基线 BMI、HOMA-IR 和 C 肽与 HbA1c 降低≥0.5%显著相关（P<0.05）。
维拉帕米对代谢无影响，并能稳定 2 型糖尿病个体的糖代谢参数。需要进一步研究探索对维拉帕米治疗有不同反应的机制。
